Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.03
KBIO's Cash to Debt is ranked higher than
79% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. KBIO: 4.03 )
KBIO' s 10-Year Cash to Debt Range
Min: 2.07   Max: No Debt
Current: 4.03

F-Score: 3
Z-Score: -4.06
M-Score: -6.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -287161.54
KBIO's Operating margin (%) is ranked lower than
56% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. KBIO: -287161.54 )
KBIO' s 10-Year Operating margin (%) Range
Min: -92975   Max: -11.19
Current: -287161.54

-92975
-11.19
Net-margin (%) -296315.38
KBIO's Net-margin (%) is ranked lower than
56% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. KBIO: -296315.38 )
KBIO' s 10-Year Net-margin (%) Range
Min: -95336.36   Max: -11.02
Current: -296315.38

-95336.36
-11.02
ROE (%) -85.71
KBIO's ROE (%) is ranked lower than
52% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. KBIO: -85.71 )
KBIO' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -85.71

ROA (%) -61.02
KBIO's ROA (%) is ranked lower than
52% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. KBIO: -61.02 )
KBIO' s 10-Year ROA (%) Range
Min: -107.14   Max: -23.07
Current: -61.02

-107.14
-23.07
ROC (Joel Greenblatt) (%) -12167.86
KBIO's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. KBIO: -12167.86 )
KBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16169.57   Max: -1061.83
Current: -12167.86

-16169.57
-1061.83
» KBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

KBIO Guru Trades in Q4 2013

Jim Simons 18,531 sh (New)
Jean-Marie Eveillard 875,000 sh (unchged)
Paul Tudor Jones Sold Out
PRIMECAP Management 4,699,975 sh (-0.14%)
» More
Q1 2014

KBIO Guru Trades in Q1 2014

Jean-Marie Eveillard 1,746,591 sh (+99.61%)
Jim Simons 29,238 sh (+57.78%)
PRIMECAP Management 4,691,475 sh (-0.18%)
» More
Q2 2014

KBIO Guru Trades in Q2 2014

Jim Simons 245,301 sh (+738.98%)
Jean-Marie Eveillard 1,746,591 sh (unchged)
PRIMECAP Management 4,475,700 sh (-4.6%)
» More
Q3 2014

KBIO Guru Trades in Q3 2014

PRIMECAP Management 4,475,700 sh (unchged)
Jean-Marie Eveillard 1,746,591 sh (unchged)
Jim Simons 126,866 sh (-48.28%)
» More
» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Add 99.61%0.01%$2.61 - $5.42 $ 1.8-51%1746591
PRIMECAP Management 2013-09-30 Add 27.84%0.01%$4.45 - $6.46 $ 1.8-68%4706675
Jean-Marie Eveillard 2013-09-30 New Buy0.01%$4.45 - $6.46 $ 1.8-68%875000
PRIMECAP Management 2013-03-31 New Buy0.03%$6 - $8 $ 1.8-74%3681675
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.76
KBIO's P/B is ranked higher than
83% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. KBIO: 1.76 )
KBIO' s 10-Year P/B Range
Min: 0.94   Max: 3.67
Current: 1.76

0.94
3.67
EV-to-EBIT -0.60
KBIO's EV-to-EBIT is ranked higher than
55% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.72 vs. KBIO: -0.60 )
KBIO' s 10-Year EV-to-EBIT Range
Min: -2.4   Max: 0.2
Current: -0.6

-2.4
0.2
Current Ratio 5.07
KBIO's Current Ratio is ranked higher than
86% of the 891 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. KBIO: 5.07 )
KBIO' s 10-Year Current Ratio Range
Min: 2.29   Max: 11.14
Current: 5.07

2.29
11.14
Quick Ratio 5.07
KBIO's Quick Ratio is ranked higher than
88% of the 890 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. KBIO: 5.07 )
KBIO' s 10-Year Quick Ratio Range
Min: 2.29   Max: 11.14
Current: 5.07

2.29
11.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.88
KBIO's Price/Net Cash is ranked higher than
99% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. KBIO: 1.88 )
KBIO' s 10-Year Price/Net Cash Range
Min: 1.7   Max: 3.12
Current: 1.88

1.7
3.12
Price/Net Current Asset Value 1.88
KBIO's Price/Net Current Asset Value is ranked higher than
98% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. KBIO: 1.88 )
KBIO' s 10-Year Price/Net Current Asset Value Range
Min: 1.7   Max: 3.12
Current: 1.88

1.7
3.12
Price/Tangible Book 1.77
KBIO's Price/Tangible Book is ranked higher than
87% of the 945 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.19 vs. KBIO: 1.77 )
KBIO' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 2.86
Current: 1.77

1.6
2.86
Earnings Yield (Greenblatt) -166.70
KBIO's Earnings Yield (Greenblatt) is ranked lower than
56% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. KBIO: -166.70 )
KBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 484.6   Max: 11814
Current: -166.7

484.6
11814

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:0KB.Germany
KaloBios Pharmaceuticals Inc. was incorporated on March 15, 2000. On February 5, 2013 the Company closed its initial public offering. The Company is a biopharmaceutical company engaged on the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families. With Humaneered antibody technology, the Company produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a clinical focus on respiratory diseases and cancer. Humaneered antibodies have tested clinically in over 250 patients with no evidence of immunogenicity. The Company identifies and develops products that treat multiple indications through proof-of-concept studies. The Company has advanced three antibodies to the clinical development stage: KB001-A, for the treatment of Pa VAP; KB004, for hematologic malignancies; and KB003, for severe asthma. KB001-A, is a Humaneered, recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody that is being developed for the prevention and treatment of infections by Pa, a gram negative bacteria that can cause pneumonia in mechanically ventilated patients and chronic respiratory infections in individuals with CF. KB004 is a Humaneered, monoclonal antibody in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. KB003 is a Humaneered, recombinant monoclonal antibody that targets and neutralizes human granulocyte macrophage colony-stimulating factor, or GM-CSF, with potential for use in inflammatory, autoimmune and other indications. Humaneered technology platform addresses issues of therapeutic antibody engineering and down-stream processing issues. The Humaneered technology is a method for converting antibodies into engineered human antibodies designed for therapeutic use, particularly for chronic conditions. The technology is designed to produce antibodies that have specificity and affinity for their target antigen, low propensity for aggregation, and a long-term stability. KB001-A, KB003, and KB004 are all Humaneered antibodies or antibody fragments. The Company currently has a collaboration with Sanofi for the development of KB001-A, and have licensed its Humaneered technology non-exclusively to Novartis and also in-licensed certain rights from, among others, UCSF and LICR. The Company owns 12 issued U.S. patents, with another issued U.S. patent owned jointly with a third party. It has an exclusive license to seven U.S. patents and owns 49 issued foreign patents. The Company's competitors include pharmaceutical companies, biotechnology companies, academic institutions, and other research organizations. The Company also competes with Valneva, MedImmune, Micromet along with Nycomed among others.
» More Articles for KBIO

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
KALOBIOS PHARMACEUTICALS INC Financials Nov 18 2014
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session Nov 14 2014
KaloBios Announces Upcoming Scientific and Investor Conference Participation Nov 11 2014
KaloBios Announces Upcoming Scientific and Investor Conference Participation Nov 11 2014
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session Nov 10 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
KaloBios Reports Third Quarter Financial Results Nov 06 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 08 2014
Publication by KaloBios and Collaborators Shows EphA3 as Target for Highly Selective Anticancer... Aug 14 2014
KaloBios (KBIO) Enters Oversold Territory Aug 13 2014
Relypsa (RLYP) Worth Watching: Stock Gains 13.3% Aug 11 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results Aug 07 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 28 2014
KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 20 2014
Will KaloBios (KBIO) Continue to Surge Higher? Jun 13 2014
KaloBios to Present at 9th Annual JMP Securities Healthcare Conference Jun 11 2014
KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% Jun 11 2014
KaloBios Pharmaceuticals (KBIO) Worth Watching: Stock Up 5.3% May 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK